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Abstract
Background: Only a minority of cancer patients benefits from the combination of EGFR-inhibition and radiotherapy
in head and neck squamous cell carcinoma (HNSCC). A potential resistance mechanism is activation of EGFR and/or
downstream pathways by stimuli in the microenvironment. The aim of this study was to find molecular targets
induced by the microenvironment by determining the in vitro and in vivo expression of proteins of the
EGFR-signaling network in 6 HNSCC lines. As hypoxia is an important microenvironmental parameter associated
with poor outcome in solid tumors after radiotherapy, we investigated the relationship with hypoxia in vitro and
in vivo.
Methods: Six human HNSCC cell lines were both cultured as cell lines (in vitro) and grown as xenograft tumors
(in vivo). Expression levels were determined via western blot analysis and localization of markers was assessed via
immunofluorescent staining. To determine the effect of hypoxia and pAKT-inhibition on cell survival, cells were
incubated at 0.5% O2 and treated with MK-2206.
Results: We observed strong in vitro-in vivo correlations for EGFR, pEGFR and HER2 (rs=0.77, p=0.10, rs=0.89, p=0.03)
and rs=0.93, p=0.02, respectively), but not for pAKT, pERK1/2 or pSTAT3 (all rs<0.55 and p>0.30). In vivo, pAKT
expression was present in hypoxic cells and pAKT and hypoxia were significantly correlated (rs=0.51, p=0.04). We
confirmed in vitro that hypoxia induces activation of AKT. Further, pAKT-inhibition via MK-2206 caused a significant
decrease in survival in hypoxic cells (p<0.01), but not in normoxic cells.
Conclusions: These data suggest that (p)EGFR and HER2 expression is mostly determined by intrinsic features of
the tumor cell, while the activation of downstream kinases is highly influenced by the tumor microenvironment.
We show that hypoxia induces activation of AKT both in vitro and in vivo, and that hypoxic cells can be specifically
targeted by pAKT-inhibition. Targeting pAKT is thus a potential way to overcome therapy resistance induced by
hypoxia and improve patient outcome.
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Background
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer with 500.000 new diag-
noses per year worldwide [1]. Recent research findings
have resulted in a better understanding of the biologic
features of HNSCC tumors, which has led to the devel-
opment of new therapeutic agents targeting specific
molecules important for tumor growth and cell survival.
One of these new successful targeting agents is Cetuximab,
a monoclonal antibody against the Epidermal Growth
Factor Receptor (EGFR), which improves survival in
HNSCC patients treated with radiotherapy [2]. How-
ever, despite this success, a significant proportion of
patients does not benefit from the addition of anti-
EGFR treatment. In addition, most clinical trials find
no correlation between EGFR expression assessed by
immunohistochemistry and response to treatment with
EGFR inhibitors [3].
To improve patient outcome with these new intensi-
fied treatments, a large amount of research has been
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focused on identifying resistance mechanisms using
different in vitro models [4-7]. However, it is uncertain
to what extent these in vitro results can be translated
towards the in vivo situation. A potential reason for
the absence of a correlation between EGFR expression
and response to EGFR inhibition is the EGFR-
independent activation of signaling pathways, including
the phosphatidylinositol-3-kinase (PI3-K)/protein kinase
B (AKT) pathway, by other stimuli in the microenviron-
ment [8]. The tumor microenvironment is complex and
includes fluctuating oxygen and nutrient gradients,
which are not present in standard 2D cell culture assays,
but which can have a great impact on tumor behavior
and treatment response. Hypoxia is an important micro-
environmental parameter known to induce the transcrip-
tion and activation of a wide variety of proteins and is
an inherent negative factor for treatment outcome in
solid tumors, including treatment outcome after radio-
therapy [9-11]. Hence, it is of great importance to dis-
cover molecular targets that could be used to specifically
kill hypoxic cells and consequently improve patient
outcome.
Therefore, the aim of this study was to find molecular
targets in the EGFR-pathway, which are induced by the
microenvironment and thus not detected in standard
in vitro assays. For this, we determined the in vitro and
in vivo expression of proteins involved in the EGFR-
signaling network in HNSCC lines both cultured as cell
lines and grown as xenograft tumors. We investigated the
tyrosine kinase receptors EGFR and human epidermal
growth factor receptor 2 (HER2), and the activated form
of kinases of the main signaling pathways downstream of
EGFR: protein kinase B (AKT), extracellular signal-
regulated kinase 1/2 (ERK1/2), and signal transducer and
activator of transcription 3 (STAT3) [12]. Using this
method, we were able to determine that pAKT, pERK1/2
and pSTAT3 were differentially expressed between cells
in culture and in tumors, as an indication that these pro-
teins were likely to be influenced by the tumor micro-
environment. More importantly, we observed that AKT is
activated by hypoxia both in vivo and in vitro and that
the hypoxic cells are more sensitive to AKT-inhibition.
These data implicate that pAKT-inhibition could be a
promising way to specifically target hypoxic tumors in the
clinic and improve outcome after a variety of treatments,
including radiotherapy and EGFR-inhibition.
Methods
Cell lines
Six human head and neck squamous cell carcinoma cell
lines (UT-SCC lines) were both cultured in vitro and
grown as xenografts in nude mice. The characteristics of
the cell lines are shown in Table 1. Cells were cultured
in T75 culture flasks, under humidified conditions
(37°C, 5% CO2), and passaged weekly or twice weekly
in DMEM containing 2 mM L-glutamine, 1% nones-
sential amino acids, 20 mM Hepes, 10 units/ml penicillin,
10 units/ml streptomycin, and 10% fetal bovine serum.
Hypoxic incubation and MK-2206 treatment
To determine expression levels after hypoxia and/or AKT-
inhibition, UT-SCC5 and UT-SCC15 cells were treated
overnight (16h) with 0 or 2 μM MK-2206 (Selleckchem,
Houston, TX, USA) under standard normoxic conditions
and thereafter incubated under normoxic conditions or
under hypoxic conditions (0.5% O2, H35 hypoxystation,
Don Whitley Scientific Ltd., West Yorkshire, UK) for 1h.
To assess cell survival after hypoxia and/or AKT-
inhibition, UT-SCC5 and UT-SCC15 cells were seeded in
96-well plates. After the cells were allowed to attach
overnight under standard normoxic conditions, 0 or
2 μM MK-2206 was added and cells were incubated
under normoxic conditions or under hypoxic conditions
(0.5% O2) for 72h. Cell survival was determined 72h
after normoxic or hypoxic incubation using a Cell-
Counting Kit-8 assay (CCK8, Sigma-Aldrich Chemie BV,
Zwijndrecht, The Netherlands).
Xenograft tumors
Animal experiments were performed using 6–8 week-old
BALB/c nu/nu mice. Of all six carcinoma cell lines, 5x106
cells were injected subcutaneously into the flank. Tumor
size was measured by the same technician twice a week.
Tumors with a diameter of 4 mm or larger were harvested
or passaged. For passaging, the tumor was excised and cut
into 1 mm3 tumor pieces. The tumor pieces were then
subcutaneously implanted into the flank. In this study
first, second, and third passage tumors were analyzed.
One hour before tumor excision, animals were injected
intraperitonally with 0.5 ml of saline containing 2 mg
pimonidazole hydrochloride (1-[(2-hydroxy-3-piperidinyl)
propyl]-2-nitroimidazole hydrochloride, Natural Pharma-
ceuticals International Inc., Research Triangle Park, NC,
USA) to label hypoxic cells. After excision, tumors were
immediately frozen in liquid nitrogen. The number of
Table 1 Characteristics of UT-SCC cell lines
Cell line TNM* Primary tumor location Type of lesion Grade
UT-SCC5 T1N1M0 Tongue Primary 2
UT-SCC8 T2N0M0 Supraglottic larynx Primary 1
UT-SCC15 T1N0M0 Tongue Recurrence 1
UT-SCC29 T2N0M0 Glottic larynx Primary 1
UT-SCC38 T2N0M0 Glottic larynx Primary 2
UT-SCC45 T3N1M0 Floor of mouth Primary 3
*TNM status of primary tumors according to the International Union against
Cancer (1997).
Note: Grade: 1, well differentiated; 2, moderately differentiated; 3, poorly
differentiated.
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harvested tumors ranged from 2 to 4 per cell line with
a total of 19.
Animals were kept in a specific pathogen-free unit in
accordance with institutional guidelines. All experiments
were approved by the Animal Experiments Committee
of the Radboud University Nijmegen Medical Centre.
Western blot analysis
To determine protein expression in vitro and in vivo, cul-
tured cells or tumor sections were lysed, cell debris was
removed by centrifugation and protein was quantitated
using a standard Bradford absorbance assay. Proteins
(25 μg per lane) were separated by SDS-PAGE and blot-
ted onto PVDF membrane. Membranes were incubated
with the appropriate primary antibodies followed by incu-
bation with HRP-conjugated antibodies. Finally, proteins
were detected with an ECL chemiluminescence system.
Antibodies against the following antigens were used:
EGFR, pEGFR (Y1173), HER2, AKT, STAT3, and HRP-
conjugated goat-anti-rabbit IgG, goat-anti-mouse IgG and
donkey-anti-goat IgG were purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). pHER2
(Y1221/1222), pAKT(S473), pERK1/2(T202/Y204), ERK1/
2, and pSTAT3(Y705) were purchased from Cell Signaling
Technology (Beverly, MA, USA) and α-tubulin was
obtained from Calbiochem (San Diego, CA, USA).
To obtain a quantitative measure for total protein ex-
pression, the integrated optical density (IOD) of the
chemiluminescent signal was measured using ImageJ
software (NIH, Bethesda, MD, USA). IOD values of all
proteins were normalized to those of α-tubulin.
Immunohistochemical staining, image acquisition and
analysis of tumor sections
To determine localization of protein expression in vivo,
frozen tumor sections (5 μm) were thawed, fixed in
acetone (4°C) and rehydrated in PBS. Two consecutive
tumor sections from each tumor were stained for pAKT
or pimonidazole in combination with EGFR and vessels.
EGFR and pAKT were stained with the same antibodies
used for western blot analysis. The antibody against
pimonidazole was a gift from J.A. Raleigh (University of
North Carolina) and 9F1 supernatant, a rat monoclonal
antibody against mouse endothelium, was a gift from
the Department of Pathology, Radboud University
Nijmegen Medical Centre. EGFR was detected by incu-
bation with Cy3-conjugated donkey-anti-goat IgG
(Jackson Immuno Research Laboratories Inc., West
Grove, PA, USA), pAKT and pimonidazole by incuba-
tion with Alexa488-conjugated donkey-anti-rabbit IgG
(Molecular Probes, Leiden, The Netherlands), and 9F1
by incubation with Alexa647-conjugated chicken-anti-rat
IgG (Molecular Probes). Stained sections were mounted
in Fluorostab (ICN Pharmaceuticals, Inc, Zoetermeer,
The Netherlands).
Stained tumor sections were scanned on a digital
image processing system consisting of a 12-bit charge-
couple device camera (Micromax, Roper Scientific Inc.,
Trenton, NJ, USA) on a fluorescence microscope
(Axioskop, Zeiss Göttingen, Germany) and a computer-
controlled motorized stepping stage, using IPLab soft-
ware. Each section was sequentially scanned three times
at 100x magnification, yielding an image of hypoxia
(pimonidazole) or pAKT-expression, an image of EGFR-
expression and an image of the vasculature structures
(9F1). One pseudo-colored composite image was recon-
structed from the individual microscope images. Using
this composite image, total tumor area was delineated
and non-tumor tissue, necrotic area and staining arti-
facts were excluded from the analysis. Thereafter, thresh-
olds for the fluorescence signals were interactively set at
intensities where the steepest gradient occurred between
background and foreground intensity levels, and grey
value images were converted to binary images. Using
ImageJ software (NIH, Bethesda, MD, USA), the fraction
positive for pAKT or hypoxia was calculated by dividing
the tumor area positive for the respective marker by the
total tumor area. The overlap fraction of EGFR and
pAKT was calculated by dividing the tumor area positive
for both markers by the tumor area positive for EGFR.
Statistics
Statistical analyses were performed using Prism 4.0c
(GraphPad Software, Inc., LA Jolla, CA, USA). Correla-
tions between parameters were assessed using the Spear-
man correlation test. The significance of differences in
cell survival between different treatments was assessed
using a Kruskal-Wallis test in combination with a
Dunn’s multiple comparison test. P-values < 0.05 were
considered to be significant.
Results
Expression of activated kinases, but not of tyrosine kinase
receptors, induced by tumor microenvironment
Using western blot analyses, expression levels of various
proteins involved in the EGFR-signaling network were
assessed in 6 different HNSCC cell lines both grown in cul-
ture (in vitro) and grown as xenograft tumors (in vivo). As
example, western blots for (p)EGFR and pAKT are shown
in Figure 1 (western blot images of (p)HER2, (p)ERK1/2
and (p)STAT3 are shown in Additional file 1: Figure S1).
The tyrosine kinase receptors EGFR and HER2 showed
a wide variation of expression levels in both cells and
tumors. Overexpression of these membrane receptors
seems to be an intrinsic feature of the cell lines as for
both EGFR and HER2 a strong correlation was found
between in vitro and in vivo expression levels (rs=0.77,
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p=0.10 and rs=0.93, p=0.02, respectively) (Figure 2A).
Although there was only a trend towards a correlation
between in vitro and in vivo EGFR expression (p=0.10),
the correlation for the activated form pEGFR was signifi-
cant (rs=0.89, p=0.03). This was not the case for pHER2
(rs=0.26, p=0.66), which showed different levels of ex-
pression in the tumors, but was invariably low in vitro.
In contrast to the tyrosine kinase receptors, no
in vitro-in vivo correlation was observed for the acti-
vated kinases pAKT, pERK1/2 or pSTAT3 (all rs<0.55
and p>0.30) (Figure 2B). The lack of correlation was pre-
dominantly due to the fact that there was a wide range
of expression levels in vitro while in vivo the kinases
were activated at relatively high levels in all tumor lines
(Figure 1 and 2B). These results suggest that stimuli in
the tumor microenvironment activate the different cell
signaling pathways and consequently lead to relatively
high in vivo levels of pAKT, pERK1/2 and pSTAT3.
pAKT expression present in hypoxic cells in vivo
A variety of stimuli within the tumor microenvironment
can activate kinases like AKT, ERK1/2 and STAT3, in-
cluding hypoxia. Therefore, EGFR, pAKT, and hypoxia
were immunohistochemically stained in tumor sections
to visualize their spatial relationship and to find a
possible explanation for the absence of a correlation be-
tween the in vitro and in vivo expression of pAKT.
We observed that EGFR expression was predomin-
antly present in tissue surrounding blood vessels,
whereas pAKT was mostly expressed further away from
the vessels in hypoxic areas indicated by pimonidazole
staining in the consecutive tumor section (Figure 3 and
Additional file 2: Figure S2). Using quantitative image
analysis, we observed that in average only 7.7% (range:
1.0-33.6%) of cells expressing EGFR also expressed
pAKT. Thus, although cells were present that expressed
both EGFR and pAKT, the overall overlap was relatively
low. Moreover, we found that the fraction of the tumor
positive for pimonidazole (hypoxic fraction) was signifi-
cantly correlated with the fraction positive for pAKT
(rs=0.51, p=0.04) (Figure 4). These results suggest that
pAKT is activated by hypoxia in an EGFR-independent
way in these tumors.
pAKT is induced by hypoxia in vitro, and is important for
cell survival under hypoxia
To confirm that hypoxia itself is an activating factor for
AKT in vivo, cells of two HNSCC lines were cultured
under hypoxic conditions (0.5% O2). One hour after
hypoxia, pAKT was indeed increased in both cell lines
Figure 1 In vitro and in vivo expression of EGFR, pEGFR, pAKT and AKT in 6 HNSCC lines. Cell lines were both cultured as cell lines
(in vitro) and grown as xenograft tumors (in vivo) and expression levels were determined with western blot. Expression of α-tubulin was used as
loading control. A) In vitro expression of EGFR, pEGFR, pAKT and AKT. B) In vivo expression of EGFR, pEGFR, pAKT and AKT. Number of harvested
tumors ranged from 2 to 4 per cell line.
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(Figure 5A). As pAKT plays an important role in cell
survival, these results suggest that hypoxic cells could be
specifically targeted by pAKT-inhibition. To test the hy-
pothesis that hypoxic cells are more sensitive to pAKT-
inhibition, both normoxic and hypoxic (0.5% O2) cells
were treated with the specific pAKT-inhibitor MK-2206
and cell survival was assessed. MK-2206 treatment
decreased pAKT expression efficiently under normoxic
and hypoxic conditions (Figure 5A). In both HNSCC cell
lines hypoxia itself did not cause a decrease in cell sur-
vival (Figure 5B). Under normoxic conditions, MK-2206
had a small, but non-significant, effect on cell survival.
However, when hypoxic cells were treated with MK-
2206 this resulted in a significant decrease in cell sur-
vival (p<0.01). These results indicate that activation of
AKT by hypoxia is important for cell survival under
hypoxic conditions and can be specifically targeted by
MK-2206.
Discussion
In recent years, a variety of newly developed targeted anti-
cancer therapies have successfully been combined with
classic therapies, including the combination of EGFR-
inhibition and radiotherapy in HNSCC [2]. However, these
Figure 2 Correlation between in vitro and in vivo expression of EGFR/HER2 and pAKT/pSTAT3/pERK1/2 in 6 HNSCC lines. A) Correlation
between in vitro and in vivo expression of EGFR and HER2. B) Correlation between in vitro and in vivo expression of pAKT, pERK1/2 and pSTAT3.
Expression was assessed by western blot analysis and depicted in relative units. The integrated optical density (IOD) was measured and all values
were normalized to those of α-tubulin by dividing the IOD value for that specific marker by the IOD value of α-tubulin. In vitro expression of
UT-SCC5 was set as standard. Error bars represent standard error of the mean and all axes are in log scale. Correlations between in vitro and
in vivo expression were assessed using the Spearman correlation test.
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new intensified combinations also induce increased tox-
icity and (acquired) resistance [3,13]. The a priori selec-
tion of patients that will respond is thus paramount, and
research has focused on the identification of resistance
mechanisms using different in vitro models. However, the
complex tumor microenvironment can also be a source of
therapy resistance. Hypoxia can have a great impact on
the behavior of a tumor cell and also on the response to
treatment [14]. Therefore, it is important to determine
which proteins are influenced by hypoxia, because these
Figure 3 Expression of EGFR, pAKT and hypoxia in vivo. Expression of EGFR and pAKT in relation to hypoxia was analyzed by
immunohistochemical analysis in UT-SCC xenograft tumors of 4 different lines. Left column: EGFR (red), pAKT (green), vessels (blue). Right column:
EGFR (red), hypoxia (green), vessels (blue). Non-specific staining present in necrotic regions. Scale bars represent 500 μm. Magnification: 100X.
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proteins could be potential targets to reduce therapy re-
sistance to a variety of treatments, including radiotherapy
and EGFR-inhibition.
In the current study, we found that the expression of
EGFR and HER2 in vitro was correlated with the in vivo
expression, which indicates that the expression of these
tyrosine kinase receptors is largely an intrinsic feature of
a tumor cell. The in vitro expression of activated EGFR
(pEGFR) was also highly correlated with the in vivo
expression, while the levels of pHER2 in vivo were
clearly higher and varied more in the xenografts than
in vitro. These observations suggest that activation of
EGFR is possibly more genetically determined, e.g. by
mutations present in the different tumor lines, while the
activation of HER2 is more determined by factors in the
tumor microenvironment that are not present in stand-
ard 2D cell culture. Also, in head and neck cancer
patients a strong correlation between EGFR and pEGFR
levels has been observed [15]. This correlation supports
our observation that the extend of activated EGFR is
predominantly influenced by EGFR overexpression and
not by other stimuli in the microenvironment.
In contrast to the tyrosine kinase receptors, no
in vitro-in vivo correlation was observed for the acti-
vated kinases pAKT, pERK1/2 or pSTAT3, indicating
that the expression of these activated kinases is influ-
enced by factors in the tumor microenvironment. Here,
we show that hypoxia is an activating stimulus for AKT
in vivo. This hypoxia-induced increase in pAKT cannot
be explained by hypoxia-induced activation of EGFR as
is observed in different in vitro models [16,17]. EGFR
expression was namely predominantly present in oxyge-
nated areas and there was a relatively low overlap be-
tween EGFR and pAKT expression in vivo. Besides these
observations in our preclinical models, mismatch in
EGFR-pAKT expression and the presence of pAKT in
hypoxic regions is also observed in HNSCC patient sam-
ples [8]. EGFR-independent upregulation of pAKT by
hypoxia has also been observed in lung cancer cells,
Figure 4 Correlation between pAKT and hypoxia in vivo.
Correlation between the pAKT and hypoxic fraction in tumors of
6 HNSCC lines was assessed with the Spearman correlation test.
Symbols represent individual tumors of the different UT-SCC lines.
Figure 5 Effect of hypoxia and MK-2206 on pAKT levels and cell survival in vitro. A) Expression of (p)AKT after treatment with MK-2206
under normoxic and hypoxic (1h, 0.5% O2) conditions in UT-SCC5 and UT-SCC15. B) Cell survival after treatment with MK-2206 under normoxic
and hypoxic (72h, 0.5% O2) conditions in UT-SCC5 and UT-SCC15. **: p<0.01 compared to control.
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whereby activation of AKT was induced via the IGF1R/
PI3K/AKT pathway [18]. Also oxidative stress, which
can occur during reoxygenation, has been shown to acti-
vate AKT in HNSCC cells [19]. Hypoxia-induced,
EGFR-independent, activation of AKT could thus be an
important resistance mechanism in HNSCC patients
treated with EGFR-inhibition and radiotherapy. Al-
though EGFR is the most commonly overexpressed tyro-
sine kinase receptor in head and neck cancer, also other
receptors are overexpressed like HER2, HER3, and IL-6
receptor [20,21], which could possibly play a role in
hypoxia-induced activation of AKT. However, we fo-
cused on our major finding that activation of AKT is a
characteristic of hypoxic cells in HNSCC and therefore a
potential target to specifically kill hypoxic cells. Exten-
sive crosstalk between different growth factor receptors,
such as EGFR and MET, has been reported [22]. These
growth factor receptors activate similar pathways, which
means that cells that overexpress multiple growth factor
receptors can sustain survival signaling even if one of
the receptors is blocked [23]. This is exemplified by the
study of Erjala et al., which also used a panel of UT-SCC
cell lines, that showed that EGFR or pEGFR levels were
not correlated, but pHER2 and HER3 levels were corre-
lated with sensitivity to EGFR-inhibition [4]. Also down-
stream signaling molecules like pAKT en pERK1/2 were
not correlated with sensitivity for EGFR-inhibition. In
our cell lines, we did also not observe that overexpres-
sion of pEGFR was consistently linked to overexpression
of pSTAT3, pAKT or pERK1/2. Therefore, it is more im-
portant to determine activation of the common down-
stream pathway, which is responsible for cell survival, as
this will be a more attractive target to overcome treat-
ment resistance than targeting one specific growth factor
receptor. In the HNSCC tumor lines studied, we indeed
show that pAKT-inhibition decreases cell survival in
hypoxic cells, but not in normoxic cells. Hypoxic cells
are resistant to a variety of treatment regimens, includ-
ing radiotherapy [9], and as pAKT signaling is an im-
portant cell survival pathway [24], targeting of pAKT in
hypoxic tumors could be a promising way to signifi-
cantly improve patient outcome. Additionally, multiple
animal studies have shown that MK-2206 also inhibits
pAKT in vivo and reduces tumor growth [25-27]. More-
over, Knowles et al. showed that MK-2206 not only
reduced primary tumor size in an orthotopic HNSCC
model, but also inhibited HNSCC migration in vitro and
reduced the number of lymph node metastases in vivo
[25]. Although the effect of AKT-inhibition on HNSCC
migration could explain the reduced metastases forma-
tion in this study, it is also known that hypoxia can in-
duce a metastatic phenotype [28]. Killing hypoxic cells
via pAKT-inhibition, as we show in this study, could
thus potentially reduce not only tumor growth, but also
the metastatic potential of the tumor. AKT is also a
highly druggable target in the clinic since multiple spe-
cific AKT inhibitors, including the inhibitor we used in
our study, are already tested in phase I/II clinical trials
and are generally well tolerated [29].
Although our data show that the microenvironment
can induce the expression of activated kinases and that
therefore expression levels in tumors do not correspond
with cells in vitro, they do not explain why we see very
little variation in total expression between the tumors. A
possible reason for this is the technique we used to de-
termine expression levels. Western blot analysis deter-
mines the total expression in all tumor cells together.
However, using immunohistochemistry we observed that
the level of expression of the different proteins varied
widely between cells in the tumors under the influence
of e.g. hypoxia and this spatial information is totally lost
by western blot analysis. Thus, possibly by determining
the expression in all cells together, these differences be-
tween individual cells level out and result in an ‘average’
level of expression, which differs relatively little between
tumors as we observed in this study. One of the main
advantages of immunohistochemistry is the possibility to
analyze specifically tumor cells. Although we used
tumors that had a large fraction of viable tumor cells
and a very low amount of stromal cells, we cannot ex-
clude the possibility that the presence of small amounts
of normal cells affected our results.
Conclusion
Our data indicate that the expression of (p)EGFR and
HER2 is largely an intrinsic feature of a tumor cell, while
the in vivo expression of activated kinases of important
cell signaling pathways can be substantially affected by
the tumor microenvironment. Moreover, we show that
AKT is activated by hypoxia both in vivo and in vitro and
that hypoxic cells are more sensitive to AKT-inhibition.
As hypoxic tumors are resistant to a variety of treatment
regimens, AKT might thus be a promising druggable
target in hypoxic tumors. Further research is warranted
to confirm our hypothesis that anti-cancer treatment
can be improved by specifically targeting hypoxic cells
with pAKT-inhibition and in which way this finding can
be optimally used to improve patient outcome in the
future.
Additional files
Additional file 1: Figure S1. In vitro and in vivo expression of (p)HER2,
(p)STAT3 and (p)ERK1/2 in 6 HNSCC lines. Cell lines were both cultured as
cell lines (in vitro) and grown as xenograft tumors (in vivo) and expression
levels were determined with western blot. A) In vitro expression of (p)
HER2, (p)STAT2 and (p)ERK1/2. B) In vivo expression of (p)HER2, (p)STAT2
and (p)ERK1/2. Number of harvested tumors ranged from 2 to 4 per cell
line.
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Additional file 2: Figure S2. Enlarged detail of Figure 3. Expression of
EGFR, pAKT and hypoxia in a tumor of UT-SCC5. Left picture: EGFR (red),
pAKT (green), vessels (blue). Right picture: EGFR (red), hypoxia (green),
vessels (blue). Magnification: 100X.
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